Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study

被引:167
作者
Wu, Ren-Rong [1 ]
Zhao, Jing-Ping [1 ]
Guo, Xiao-Feng [1 ]
He, Yi-Qun [1 ]
Fang, Mao-Sheng [1 ]
Guo, Wen-Bin [1 ]
Chen, Jin-Dong [1 ]
Li, Le-Hua [1 ]
机构
[1] Cent S Univ, Second Xiangya Hosp, Inst Mental Hlth, Hunan 410011, Peoples R China
关键词
D O I
10.1176/appi.ajp.2007.07010079
中图分类号
R749 [精神病学];
学科分类号
100205 [精神病与精神卫生学];
摘要
Objective: The purpose of this study was to assess the efficacy of metformin in preventing olanzapine-induced weight gain. Method: Forty patients with schizophrenia were randomly assigned to treatment for 12 weeks with olanzapine, 15 mg/day, plus metformin, 750 mg/day (N=20), or olanzapine, 15 mg/day, plus placebo (N=20). This investigation was conducted in a double-blind fashion. Planned assessments included body weight, body mass index, proportion of patients who gained more than 7% of their baseline weight at the end of the 12-week treatment, waist circumference, waist-to-hip ratio, fasting glucose and insulin, insulin resistance index, and scores on the Scale for the Assessment of Positive Symptoms (SAPS) and Scale for the Assessment of Negative Symptoms (SANS). Results: Of the 40 patients who were randomly assigned, 37 (92.5%) completed treatments. The weight, body mass index, waist circumference, and waist-to-hip ratio levels increased less in the olanzapine plus metformin group relative to the olanzapine plus placebo group during the 12-week follow-up period. The insulin and insulin resistance index values of the olanzapine plus placebo group increased significantly at weeks 8 and 12. In contrast, the insulin and insulin resistance index levels of the olanzapine plus metformin group remained unchanged. Significantly fewer patients in the olanzapine plus metformin group relative to patients in the olanzapine plus placebo group increased their baseline weight by more than 7%, which was the cutoff for clinically meaningful weight gain. There was a significant decrease in SAPS and SANS scores within each group from baseline to week 12, with no between-group differences. Metformin was tolerated well by all patients. Conclusions: Metformin was effective and safe in attenuating olanzapine-induced weight gain and insulin resistance in drug-naive first-episode schizophrenia patients. Patients displayed good adherence to this type of preventive intervention.
引用
收藏
页码:352 / 358
页数:7
相关论文
共 41 条
[1]
Weight gain in first-episode psychosis [J].
Addington, J ;
Mansley, C ;
Addington, D .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2003, 48 (04) :272-276
[2]
Metformin-associated lactic acidosis treated with continuous renal replacement therapy [J].
Alivanis, P ;
Giannikouris, I ;
Paliuras, C ;
Arvanitis, A ;
Volanaki, M ;
Zervos, A .
CLINICAL THERAPEUTICS, 2006, 28 (03) :396-400
[3]
Allison DB, 1999, AM J PSYCHIAT, V156, P1686
[4]
Andreasen N, 1984, SCALE ASSESSMENT POS
[5]
Drug therapy - Metformin [J].
Bailey, CJ ;
Turner, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (09) :574-579
[6]
Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms [J].
Cleasby, ME ;
Dzamko, N ;
Hegarty, BD ;
Cooney, GJ ;
Kraegen, EW ;
Ye, JM .
DIABETES, 2004, 53 (12) :3258-3266
[7]
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial [J].
Evans, S ;
Newton, R ;
Higgins, S .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2005, 39 (06) :479-486
[8]
The effect of metformin on the metabolic abnormalities associated with upper-body rat distribution [J].
Fontbonne, A ;
Charles, MA ;
JuhanVague, I ;
Bard, JM ;
Andre, P ;
Isnard, F ;
Cohen, JM ;
Grandmottet, P ;
Vague, P ;
Safar, ME ;
Eschwege, E .
DIABETES CARE, 1996, 19 (09) :920-926
[9]
Ganguli R, 1999, J CLIN PSYCHIAT, V60, P20
[10]
Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30 [J].
Glueck, CJ ;
Fontaine, RN ;
Wang, P ;
Subbiah, MTR ;
Weber, K ;
Illig, E ;
Streicher, P ;
Sieve-Smith, L ;
Tracy, TM ;
Lang, JE ;
McCullough, P .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2001, 50 (07) :856-861